8月19日，艾伯维公司盘中上涨3.03%，报257.915美元/股，成交额4.05亿美元。
消息面上，近期多家华尔街投行密集上调艾伯维目标价。富国银行于8月17日将目标价由295美元上调至300美元，维持跑赢大盘评级；Wolfe于8月13日将评级从同业表现上调至跑赢大盘，目标价定为300美元；法国巴黎银行亦将目标价由218美元大幅上调至247美元。当前FactSet统计的分析师平均目标价已升至278.73美元，评级共识为增持。
管线方面，艾伯维近日在ClinicalTrials平台登记了从荣昌生物引进的PD-1/VEGF双抗RC148全球III期临床试验，头对头对照帕博利珠单抗联合化疗用于一线非小细胞肺癌，标志着该资产进入后期开发阶段，进一步丰富公司肿瘤管线布局。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.